These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15468279)

  • 21. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey.
    Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J
    Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of bladder contractility on short-term outcomes of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate.
    Paick JS; Um JM; Kwak C; Kim SW; Ku JH
    Urology; 2007 May; 69(5):859-63. PubMed ID: 17482922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data from frequency-volume charts versus maximum free flow rate, residual volume, and voiding cystometric estimated urethral obstruction grade and detrusor contractility grade in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Van Venrooij GE; Eckhardt MD; Boon TA
    Neurourol Urodyn; 2002; 21(5):450-6. PubMed ID: 12232879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between lower urinary tract symptoms and erectile dysfunction.
    Aslan G; Cavus E; Karas H; Oner O; Duran F; Esen A
    Arch Androl; 2006; 52(3):155-62. PubMed ID: 16574595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up.
    Hamann MF; Naumann CM; Seif C; van der Horst C; Jünemann KP; Braun PM
    Eur Urol; 2008 Oct; 54(4):902-7. PubMed ID: 18502565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between a new visual prostate symptom score (VPSS) and uroflowmetry parameters in men with lower urinary tract symptoms.
    Heyns CF; van der Walt CL; Groeneveld AE
    S Afr Med J; 2012 Mar; 102(4):237-40. PubMed ID: 22464506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Value of preoperative urodynamics to the prognosis of transurethral prostate resection for benign prostatic hyperplasia].
    Cheng W; Gao JP; Zhang ZY; Ge JP; Xue S
    Zhonghua Nan Ke Xue; 2005 Mar; 11(3):207-9. PubMed ID: 15804115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the short-term outcome of transurethral resection of the prostate affected by preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor overactivity?
    Tanaka Y; Masumori N; Itoh N; Furuya S; Ogura H; Tsukamoto T
    Int J Urol; 2006 Nov; 13(11):1398-404. PubMed ID: 17083391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up?
    Rigatti L; Naspro R; Salonia A; Centemero A; Ghezzi M; Guazzoni G; Briganti A; Rigatti P; Montorsi F
    Urology; 2006 Jun; 67(6):1193-8. PubMed ID: 16750253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms.
    Vesely S; Knutson T; Damber JE; Dicuio M; Dahlstrand C
    Scand J Urol Nephrol; 2003; 37(4):322-8. PubMed ID: 12944191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    van Venrooij GE; van Melick HH; Eckhardt MD; Boon TA
    Urology; 2008 Mar; 71(3):469-74. PubMed ID: 18342189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate.
    Volkan T; Ihsan TA; Yilmaz O; Emin O; Selcuk S; Koray K; Bedi O
    Eur Urol; 2005 Oct; 48(4):608-13. PubMed ID: 16135396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased postvoid residual volume after measuring the isovolumetric bladder pressure using the noninvasive condom catheter method.
    de Zeeuw S; van Mastrigt R
    BJU Int; 2007 Dec; 100(6):1293-7. PubMed ID: 17979926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.